OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Urticarial vasculitis	112
Giant cell arteritis: update on pathogenesis and clinical implications	66
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	59
Current approach to muscle imaging in myositis	54
Editorial introduction	51
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	44
Current views on lupus in children	43
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	34
Editorial introductions	32
Axial spondyloarthritis guidelines – aiming for maximum impact	31
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	30
The gut microbiota in spondyloarthritis: an update	30
Osteoporosis epidemiology using international cohorts	30
Optimizing reproductive health management in lupus and Sjogren's syndrome	30
Rheumatoid arthritis – the challenge of heterogeneity	28
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	26
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	25
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	24
Editorial introductions	24
Updates on translational and clinical research in systemic sclerosis	24
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	24
Ribosome dysfunction in osteoarthritis	23
Update on gout management: what is old and what is new	22
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	21
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	20

Editorial introductions	18
Defining and managing flares in axial spondyloarthritis	18
Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	18
Editorial introduction	17
Epidemiology of myositis	17
Haematopoietic stem cell transplantation in paediatric rheumatic disease	17
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	17
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment	17
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	16
Raynaud's phenomenon and digital ulcers: advances in evaluation and management	16
Health inequities in the rheumatic diseases of childhood	16
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	16
Animal models of vasculitis	15
Editorial introductions	15
Gout and the COVID-19 pandemic	15
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	14
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	14
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	14
Editorial introductions	13
AI am the future: artificial intelligence in pediatric rheumatology	13
New developments related to lung complications in pediatric rheumatic disease	12
Diagnosis and management of primary heart involvement in systemic sclerosis	11
Epidemiology of osteoarthritis: literature update 2022–2023	11
Emerging biologic therapies for systemic lupus erythematosus	11
Editorial introductions	11
Insights into the molecular landscape of osteoarthritis in human tissues	11
Investigating gout flares: beyond a definition	11
Insights into origins and specificities of autoantibodies in systemic sclerosis	11
Polymyositis: does it really exist as a distinct clinical subset?	11
Biomarker discovery in psoriatic disease	11
Management of postinfectious inflammatory arthritis	10
Heart involvement in systemic sclerosis: emerging concepts	10
Exploring challenges in the management and treatment of inclusion body myositis	10
The association of Behçet's syndrome with HLA-B51 as understood in 2021	10
Vasculitis and the NLRP3 inflammasome	10
Editorial introduction	10
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	9
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	9
Animal models in systemic sclerosis: an update	9
The contribution of endothelial cells to tissue fibrosis	9
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	9
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	9
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	9
Current management of giant cell arteritis and its complications	9
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	9
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	8
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	8
Calcinosis in systemic sclerosis	8
Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results	8
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis	8

New therapies in anti-MDA5 antibody-positive dermatomyositis	8
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	8
Update on muscle imaging in myositis	7
Clinical endpoints in myositis: challenges and ways forward	7
Osteoarthritis gene therapy in 2022	7
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis	7
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	7
Contribution of keratinocytes to dermal fibrosis	6
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	6
Bone in osteoarthritis: imaging and interventions	6
Takayasu arteritis	6
Recent advances in immunometabolism in rheumatic diseases	6
Quo vadis reactive arthritis?	6
Describing calcium pyrophosphate deposition: undoing the tower of Babel!	6
What are mice teaching us about psoriatic arthritis?	6
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	6
Epidemiology of systemic vasculitis	6
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024	6
Safety updates in novel therapeutics for pediatric rheumatic disease	6
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate	5
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	5
Go or no-go for treat-to-target in axial spondyloarthritis?	5
Rethinking spondyloarthritis: beyond lumping and splitting	5
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	5
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	5
Renal disease in pediatric rheumatology	5
The impact of the COVID-19 pandemic on the field of pediatric rheumatology	5
Metabolic perturbations in systemic sclerosis	5
Should CAR-T cells be used as monotherapy?	5
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	5
Scleroderma autoantibodies in guiding monitoring and treatment decisions	5
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	4
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease	4
Advances in osteoarthritis imaging	4
Disease modification in axial spondyloarthritis – still a controversy?	4
Omics studies in Behçet's disease	4
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	4
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	4
Editorial introduction	4
Calcinosis in systemic sclerosis	4
Advances in understanding and examining lymphatic function: relevance for understanding autoimmunity	4
Editorial introduction	4
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	4
Understanding psoriatic disease at single-cell resolution: an update	3
Is osteoarthritis a mitochondrial disease? What is the evidence	3
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	3
Editorial myositis and myopathies	3
Drug therapy in juvenile spondyloarthritis	3
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	3
An update on inflammation in antiphospholipid syndrome	3
Human genetics of Whipple's disease	3
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	3
Differential diagnosis of necrotizing myopathy	3
Regulatory T cells and systemic vasculitis	3
Physical exercise for the management of systemic autoimmune myopathies: recent findings, and future perspectives	3
Editorial introductions	3
The impact of omics research on our understanding of osteoarthritis and future treatments	3
An update on topical therapies for psoriasis	3
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities	3
Methods for objective assessment of skin involvement in systemic sclerosis	3
Vaccination updates and special considerations for systemic lupus erythematosus patients	3
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	3
SGLT-2 inhibitors: new horizons for rheumatologists	3